How does the REIT’s valuation multiples (FFO P/E, EV/EBITDA) compare to its main competitors? | GMRE (Aug 06, 2025) | Candlesense
GMRE

How does the REIT’s valuation multiples (FFO P/E, EV/EBITDA) compare to its main competitors?

Answer

The press release you referenced only announces Global Medical REIT’s (ticker GMRE) second‑quarter 2025 financial results. It does not include any details on the company’s valuation multiples—such as its Funds‑From‑Operations (FFO) price‑to‑earnings (P/E) ratio, enterprise‑value‑to‑EBITDA (EV/EBITDA) multiple, or comparable metrics for its peer group.

Because those specific figures aren’t disclosed in the release, I can’t directly compare GMRE’s FFO P/E or EV/EBITDA to those of its main competitors from this source alone.

What to Do Next

If you need a side‑by‑side comparison of GMRE’s valuation multiples versus peers (e.g., Healthpeak Properties (HPG), Medical Properties Trust (MPW), Surgery Center Properties (SCPC), etc.), you’ll typically gather the data from one or more of the following places:

Source How to Use It
Company’s Quarterly/Annual Filings (10‑Q, 10‑K) The “Management’s Discussion & Analysis” (MD&A) section often lists FFO, EBITDA, and sometimes the corresponding valuation ratios.
Investor Presentations / Earnings Call Transcripts Management sometimes provides forward‑looking guidance on FFO P/E or EV/EBITDA, or at least the raw FFO/EBITDA numbers you can convert to multiples using the current share price and market‑cap data.
Financial Data Platforms (Bloomberg, FactSet, S&P Capital IQ, Thomson Reuters Eikon) These services calculate and display FFO P/E, EV/EBITDA, and other REIT‑specific multiples for both the subject company and its peer set.
Industry Research Reports Analysts’ reports on “Medical REITs” often include a valuation‑multiple table comparing the top players.
SEC’s EDGAR “Company Filings” Search Look for “valuation multiples,” “FFO,” or “EBITDA” in the filing’s footnotes or supplemental tables.

Steps to compute the multiples yourself (if you have the raw numbers):

  1. FFO P/E

    • FFO = Net income + (depreciation & amortization) – (gains on asset sales) – (interest expense).
    • FFO per share = FFO Ă· diluted shares outstanding.
    • FFO P/E = Current share price Ă· FFO per share.

  2. EV/EBITDA

    • Enterprise Value (EV) = Market‑cap + total debt – cash & cash equivalents.
    • EBITDA = Net income + interest + taxes + depreciation & amortization.
    • EV/EBITDA = EV Ă· EBITDA (or EBITDA per share, if you prefer the per‑share version).

  3. Peer Comparison

    • Pull the same numbers for each competitor and place them in a table.
    • Highlight where GMRE sits relative to the median or mean of the peer set (e.g., “GMRE’s EV/EBITDA of 12.3× is below the peer median of 13.8×, indicating a modest discount.”).

Quick Takeaway (Based on Typical Industry Ranges)

While I can’t provide the exact numbers for GMRE without additional data, here’s a general sense of where medical‑REIT multiples tend to fall (as of mid‑2025):

Metric Typical Range for Large‑Cap Medical REITs
FFO P/E 15 – 25×
EV/EBITDA 10 – 14×

If GMRE’s multiples are inside or below these ranges, the market may be pricing the stock at a discount relative to peers; if they’re above, the stock could be viewed as premium‑valued (perhaps due to higher growth expectations, superior asset quality, or stronger balance‑sheet metrics).

Bottom Line

  • The press release you cited does not contain the valuation multiples needed for a direct comparison.
  • To answer the question, you’ll need to retrieve the relevant financial data from GMRE’s SEC filings, earnings call materials, or a financial data platform, then calculate or pull the FFO P/E and EV/EBITDA figures for both GMRE and its main competitors.

If you can provide the specific FFO, EBITDA, market‑cap, debt, and cash figures (or point me to a source that lists the multiples), I’d be happy to run the calculations and give you a precise comparative analysis.

Other Questions About This News

Did the REIT announce any new acquisitions or disposals during the quarter? How did occupancy levels change during the quarter and what is the current portfolio occupancy? How did the REIT’s credit rating change, if at all, following the release? What was the revenue growth rate versus the prior quarter and year‑over‑year? Are there any regulatory or policy changes on the horizon that could affect the REIT’s operations or valuation? What is the REIT’s current debt‑to‑equity ratio and any recent changes in leverage? What capital expenditures (CapEx) were undertaken, and how do they impact the balance sheet and cash flow? How does the current dividend yield compare to other medical REITs and to the REIT’s own historical yield? Did the REIT provide any guidance for Q3 2025 or full‑year 2025, and how does it align with market expectations? What impact, if any, did macro‑economic factors (interest rates, healthcare demand) have on the results? Are there any significant lease expirations or renewal activity that could affect future cash flows? What is the outlook for rental growth in the medical office sector and how might it affect the REIT’s future performance? What are the key drivers behind any change in net operating income (NOI) this quarter? How does the reported earnings per share compare to analyst consensus estimates for Q2 2025?